FAZA PET Scan for Prostate Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to look for low levels of oxygen (hypoxia) in prostate cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how prostate cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking the drug disulfiram (Antabuse).
How does the FAZA PET Scan treatment for prostate cancer differ from other treatments?
The FAZA PET Scan for prostate cancer is unique because it uses a specific imaging agent to detect areas of low oxygen in tumors, which can help identify aggressive cancer cells. This approach is different from traditional treatments that focus on targeting androgen receptors or using general imaging techniques.12345
Eligibility Criteria
This trial is for men over 18 with prostate cancer who plan to receive radiotherapy, hormonal therapy, or other systemic treatments. They must be able to consent and lie supine for an hour. It's not for those over 136 kg, taking disulfiram, or with MRI contraindications (unless the target lesion isn't the prostate).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo PET FAZA imaging to assess tumor hypoxia
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor